Brainstorm Cell TherapeuticsBCLI
Market Cap: $20.5M
About: Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
Employees: 29
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
84% more capital invested
Capital invested by funds: $2.22M [Q1] → $4.08M (+$1.87M) [Q2]
67% more call options, than puts
Call options by funds: $72K | Put options by funds: $43K
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
9.1% more ownership
Funds ownership: 8.33% [Q1] → 17.43% (+9.1%) [Q2]
0% more funds holding
Funds holding: 47 [Q1] → 47 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Maxim Group Jason McCarthy 25% 1-year accuracy 5 / 20 met price target | 677%upside $2 | Buy Upgraded | 11 Jul 2024 |